Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden-Reference-Cited by-同舟云学术

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

Published:2013-05-28 Issue:1 Volume:3 Page:35-43
ISSN:2195-5840
Container-title:Biologics in Therapy
language:en
Short-container-title:Biol Ther

Author:

Flodmark Carl-Erik,Lilja Katarina,Woehling Heike,Järvholm Kajsa

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1007/s13554-013-0011-z

Reference18 articles.

1. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7:S57–67.

2. Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011;9:934–42.

3. Covic A, Cannata-Andia J, Cancarini G, et al. Biosimilars and biopharmaceuticals: what the nephrologists need to know—a position paper by the ERA-EDTA Council. Nephrol Dial Transplant. 2008;23:3731–7.

4. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther. 2010;10:1011–8.

5. Omnitrope® European Public Assessment Report 2008. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000607/WC500043692.pdf . Accessed 3 Nov 2011.

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Community pharmacists' preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey;Exploratory Research in Clinical and Social Pharmacy;2021-12

2. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review;Advances in Therapy;2021-11-15

3. Switching from originator recombinant growth hormone (Genotropin™) to biosimilar (CRISCY™): Results from a 6-month, multicentric, non-inferiority, extension trial.;Growth Hormone & IGF Research;2021-02

4. Physicians’ perceptions of the uptake of biosimilars: a systematic review;BMJ Open;2020-05

5. Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies;BMC Endocrine Disorders;2020-04-29